International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Before randomization, a CCR (standard induction chem...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Dombret, Hervé, Seymour, John F., Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Noppeney, Richard, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Steve, Lucy, Lela M., Beach, C. L., Döhner, Hartmut
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2015
Aiheet:
Plenary Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504945/
https://ncbi.nlm.nih.gov/pubmed/25987659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-621664
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia